• Explore /
  • Poster
  • / Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.

Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.

Abstract Poster

Authors

Erika Hamilton

Erika Paige Hamilton

Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Erika Paige Hamilton , Valerie Malyvanh Jansen , Emily Nash Nash Smyth , Daniel Schlauch , Gebra Cuyun Carter , Melinda D Willard , Amanda Misch , Lee Bowman , Yajun Emily Zhu , Samuel McNeely , Aimee Bence Lin , Shaita Picard , Kimberly Blackwell , Howard A. Burris III, David R. Spigel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT01763788

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1042)

DOI

10.1200/JCO.2019.37.15_suppl.1042

Abstract #

1042

Poster Bd #

123

Abstract Disclosures

Similar Posters

First Author: Matthew P. Goetz

First Author: Albert Grinshpun

First Author: Malinda T West

First Author: Fabrice Andre